





# Extended Depth Of Focus IOL (EDOF)


EDOF IOLs have become a focus of attention in IOL selection for near and intermediate vision.



















### **Patients and Methods**

- Study design: Retrospective observational study
- Study site: Al Watany Eye Hospital, Watany Research and Development Center (WRDC), Cairo
- Study duration: Jan 2017 to Dec 2017
- The study was approved by the WRDC ethics committee under the regulations of the Helsinki guidelines.
- Statistical analysis was done using SPSS by IBM version 21 using paired samples t-test.







## **Patients and Methods**

#### **Inclusion Criteria**

- Presbyopic patients seeking refractive surgery with complete spectacle independence.
- Fall within the available IOL power range
- Qualify for bilateral implantation.


#### **Exclusion Criteria**

- Have unrealistic expectations about their outcomes.
- Have a preexisting ocular pathology, such as severe dry eye, uncontrolled glaucoma, keratoconus or uveitis.
- Previous corneal surgery.

### **Patients and Methods**

### Surgical Technique:

- The EDOF IOL used in this study is *Tecnis Symfony* by Johnson & Johnson.
- All cataract surgeries were performed using a standard phacoemulsification technique or a femtosecond laser–assisted technique.
- Routine protocols for postoperative care were received.



**Group A** (micro-monovision) Preoperative vs postoperative data in the dominant eye

Age: 55 years ± 8.6 (44:70) Gender: 43% females Follow up: 5.6 months ± 2.3


Dominant eye (Emmetrope)							
	Mean		SD		Range Value		
	Pre	Post	Pre	Post	Pre	Post	
UDVA	0.48	0.97	± 0.25	± 0.25	0.2 : 0.9	0.9 : 1.0	
BDVA	0.87	1.0	± 0.17	± 0.0	0.6 : 1.0	1.0	
SE (D)	-1.05	- 0.51	± 2.65	± 0.15	- 4.87 : + 2.75	- 0.75 : - 0.37	
Cylinder (D)	-0.82	- 0.57	± 0.20	± 0.15	- 1.00 : 0.00	-0.75 : 0.00	

### Group A (micro-monovision) Preoperative vs postoperative data in the non-dominant eye

**Age:** 55 years ± 8.6 (44:70) **Gender:** 43% females

Follow up: 5.6 months ± 2.3

Non-dominant eye (Myope)						
	Mean		SD		Range Value	
	Pre	Post	Pre	Post	Pre	Post
UDVA	0.54	0.97	± 0.25	± 0.04	0.1:0.9	0.9 : 1:0
BDVA	0.90	1.0	± 0.17	± 0.0	0.7 : 1.0	1.0
SE (D)	- 1.14	- 0.91	± 2.63	± 0.23	- 5.25 : + 2.50	-0.67 : -0.25
Cylinder (D)	- 0.85	- 0.46	± 0.33	± 0.30	- 1.00 : - 0.25	-0.75 : 0.0



Group A (micro-monovision)

	Non-dominant eye (myope)	Dominant eye (emmetrope)
<b>Efficacy Index</b> (postoperative UDVA / preoperative BDVA)	1.07	1.11
Predictability Index (postoperative BDVA / postoperative UDVA)	1.03	1.03
Safety Index (postoperative BDVA /preoperative BDVA)	1.11	1.14


Results Group B (non-monovision) Preoperative vs postoperative data in the dominant eye							
<b>Age:</b> 52 years ± 2.2 (44:64) <b>Gender:</b> 28% females <b>Follow up:</b> 6.2 months ± 1.8							
Dominant eye (Emmetrope)							
	Mean		SD		Range Value		
	Pre	Post	Pre	Post	Pre	Post	
UDVA	0.67	1.0	± 0.23	± 0.0	0.3 : 0.9	1.0	
BDVA	0.97	1.0	± 0.07	± 0.0	0.8 : 1.0	1.0	
SE (D)	- 0.87	- 0.16	± 1.98	± 0.20	- 3.37 : + 2.37	-0.37 : -0.25	
Cylinder (D)	- 0.75	- 0.36	± 0.34	± 0.24	- 1.00: 0.0	-0.75 : 0.0	

### **Group B** (non-monovision) Preoperative vs postoperative data in the non-dominant eye

**Age:** 52 years ± 2.2 (44:64) **Gender:** 28% females


Follow up: 6.2 months ± 1.8


Non-dominant eye (Emmetrope)						
	Mean		SD		Range Value	
	Pre	Post	Pre	Post	Pre	Post
UDVA	0.62	0.98	± 0.24	± 0.3	0.2 : 0.9	0.9 : 1:0
BDVA	0.94	1.0	± 0.11	± 0.0	0.7 : 1.0	1.0
SE (D)	-1.10	- 0.26	± 2.10	± 0.08	-3.25 : +2.87	-0.37 : -0.12
Cylinder (D)	-0.46	- 0.17	± 0.62	± 0.27	-1.00 : 0.0	-0.75 : 0.0




Group B (non-monovision)


	Non-dominant eye (myope)	Dominant eye (emmetrope)
Efficacy Index (postoperative UDVA / preoperative BDVA)	1.04	1.20
<b>Predictability Index</b> (postoperative BDVA / postoperative UDVA)	1.02	1.00
Safety Index (postoperative BDVA / preoperative BDVA)	1.06	1.03








Complications	
<ul> <li>Laser enhancement to correct residual refractive errors wa performed in 1 eye (2.5%) in Group A.</li> <li>Treatment for corneal dryness (cyclosporine for 1-2 months)</li> </ul>	-
was needed in 6 eyes (15%) in both groups.	







Micro-monovision can be an added value tool to improve the near vision satisfaction in patients undergoing RLE with EDOF IOL implantation without affecting the quality of vision.



